Altria, the maker of Marlboro cigarettes, has sued the U.S. Food and Drug Administration over its system for reviewing new tobacco products.
The Altria FDA lawsuit seeks major changes to a process that tobacco companies say has become slow and difficult to navigate.
Altria filed the case in federal court in Lubbock, Texas. The company argues that lengthy reviews have hurt its ability to compete in the U.S. market.
Altria Challenges FDA Review Delays
Under U.S. law, the FDA must review new tobacco products before companies can legally sell them.
The agency considers whether a product could provide a public health benefit. It also examines whether the product could increase nicotine addiction among young people.
However, Altria says the current system has created a huge backlog.
The company argues that some applications have remained under review for years. As a result, tobacco companies face uncertainty while unauthorized products continue to gain ground.
Company Targets 180-Day Review Requirement
A major part of Altria’s case involves the legal deadline for FDA decisions.
Altria argues that federal law requires the agency to make decisions on applications within 180 days.
According to the complaint, the FDA has never consistently met that deadline.
The company says the delays have placed legal tobacco businesses at a disadvantage.
On! Nicotine Pouches at Center of Dispute
Altria specifically pointed to its On! nicotine pouch products.
The company argues that regulatory delays have prevented these products from reaching consumers quickly enough.
At the same time, Altria says foreign competitors and other companies selling unauthorized products have captured market share.
Therefore, the company wants the court to force the FDA to create a new review system.
FDA Defends Its Regulatory Role
The FDA said it takes the legal challenge seriously.
The agency also stressed that it wants to expand access to potentially less harmful alternatives for adult smokers.
At the same time, officials said protecting young people remains a priority.
The FDA is responsible for balancing those concerns when reviewing new tobacco products.
Tobacco Industry Faces Long Application Backlog
The dispute comes after years of frustration across the tobacco industry.
Many applications for vapes and nicotine pouches have faced lengthy reviews. Some have remained unresolved for more than six years.
That situation has affected major companies, including Altria, Philip Morris International and British American Tobacco.
Meanwhile, companies continue to challenge FDA decisions and review procedures through the courts.
Altria Points to Recent FDA Changes
Altria also argues that recent FDA policy changes support its position.
The agency has introduced measures involving nicotine pouches and certain flavored vaping products.
For example, the FDA created a fast-track pathway for some nicotine pouch applications.
However, Altria says applications for its products remained pending even after the agency’s target date for decisions passed.
The company believes that situation demonstrates the weaknesses of the current system.
Lobbying Has Increased Pressure on FDA
The tobacco industry has also increased pressure on Washington over the regulatory system.
Companies have pursued legal challenges while lobbying the Trump administration for changes.
Those efforts have coincided with several regulatory developments.
However, public health advocates have strongly criticized the industry’s approach.
Public Health Groups Raise Concerns
Critics argue that changing the review process could weaken protections for consumers.
Brian King, a former head of the FDA’s Center for Tobacco Products, accused Altria of seeking to lower the scientific standards established by Congress.
Public health organizations have separately challenged FDA policies that they say could allow unauthorized nicotine products to remain on the market.
The competing legal arguments show how difficult it is to balance adult smoking alternatives with youth protection.
What Altria Wants From the Court
Altria and its co-plaintiffs are asking the court to set aside the current review system.
They also want the FDA to develop a new process for handling tobacco product applications.
The company says reform would make the system more predictable and efficient.
However, the court will have to consider whether the FDA has violated its legal obligations and what changes, if any, should follow.
Why the Lawsuit Matters
The Altria FDA lawsuit could have wider consequences for the U.S. tobacco market.
A major overhaul could affect how quickly companies introduce nicotine pouches, vapes and other new products.
It could also change the regulatory environment for Altria’s major competitors.
For now, the case adds another legal challenge to an already controversial tobacco regulatory system.
Altria Says the System Is Broken
Altria says it filed the complaint before a statutory deadline because it wants to address what it considers a long-running problem.
The company has described the current system as broken.
Meanwhile, the FDA remains responsible for protecting public health while reviewing new tobacco products.
As the lawsuit moves forward, the outcome could determine whether the agency faces greater pressure to speed up its review process.
For tobacco companies, the case is about market access and regulatory certainty. For public health advocates, however, the central question remains whether any changes can protect consumers while maintaining strong scientific standards.
